A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies

This study has been completed.

Study NCT00051597 Information provided by Seattle Genetics, Inc.

First Received: January 13, 2003 Last Updated: June 23, 2005 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given